BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

North America

Biomatter Raises $18 Million to Accelerate AI-Designed Enzymes From Lab to Market

AstraZeneca, BASF, and Sanofi among 25+ enterprise customers, with more than 50 custom enzymes delivered Proceeds will grow the commercial team and US p...

November 13, 2026 | News

Pfizer Secures Up to $1.5 Billion From Blackstone to Advance Monthly GLP-1 Programme

Blackstone to provide Pfizer up to $1.5 billion through 2028 to support clinical program for GLP-1 receptor agonist Pfizer Inc. (NYSE: PFE) and Blackstone...

November 13, 2026 | News

Abbisko’s PIMJETMI Secures FDA Approval for Symptomatic Tenosynovial Giant Cell Tumour

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), dem...

November 12, 2026 | News

IASO Bio Secures China IND Approval for In Vivo CAR-T Therapy IASO208

First lentiviral-vector-based in vivo CAR-T product from China to receive a U.S. FDA IND clearance; a Phase Ib study in R/R B-NHL will be initiated directl...

November 12, 2026 | News

FDA Approves Promega OncoMate MSI Dx System to Guide KEYTRUDA Treatment

The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate MSI Dx Analysis System designed to identify patients with solid tumors with h...

November 12, 2026 | News

Innovent’s Tafolecimab Monotherapy Cuts LDL Cholesterol by More Than 60% in Phase 3 Trial

SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks ...

November 10, 2026 | News

Vir Biotechnology’s Hepatitis Delta Combo Suppresses Virus to Undetectable Levels in All 28 Week 96 Completers

Data presented at AASLD The Liver Meeting demonstrated 100% of participants (28/28) who completed Week 96 of combination therapy reached undetectable v...

November 10, 2026 | News

OncoC4 Reports 33% Response Rate for Cesalatamig in Lung Cancer Resistant to PD-(L)1 Therapy

33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks in patients with PD-(L)1-resistant/refrac...

November 09, 2026 | News

VS Pharmtech Advances Radiotherapy Enhancer VS-101 to Phase 2 in the US

Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anti...

November 09, 2026 | News

Differentia Bio Reports Clinical Support for AI-Predicted Treatment Strategies in IgG4-Related Disease

From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharma...

November 05, 2026 | News

Lonza to Acquire Five US CDMO Sites from Merck KGaA to Double Manufacturing Footprint

Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US footprint to nine CDMO sites wit...

November 04, 2026 | News

Alkermes Advances Orexin-Based Depression Treatment into Phase II Clinical Trial

Alkermes plc announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants ...

November 02, 2026 | News

Parse Biosciences and Nomic Bio Launch 100-Million-Cell Immune Dataset to Advance AI Drug Discovery

Parse Biosciences, a leading provider of scalable and publicly available single-cell sequencing technology, a subsidiary of QIAGEN, andNomic Bio, a leader ...

November 02, 2026 | News

Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...

October 30, 2026 | News

Stay Connected